Novartis presented data showing its LCZ696 heart drug reduced cardiovascular deaths by 20% when compared with a rival treatment, suggesting the Swiss group has a multibillion-dollar product in the making.
WSJ.com: What's News US, Wall Street Journal
Sat, 08/30/2014 - 4:15am
Novartis presented data showing its LCZ696 heart drug reduced cardiovascular deaths by 20% when compared with a rival treatment, suggesting the Swiss group has a multibillion-dollar product in the making.